Iovance Biotherapeutics Sydney, New South Wales, Australia Posted 2026-11-04

This listing's locations Sydney, Current South Wales, Australia

Department: 0045-GLOBAL COMMERCIAL

Iovance Biotherapeutics , Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers.

The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit www.iovance.com .

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCaresTM are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance's broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com .

Overview

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumour-infiltrating lymphocyte (TIL) therapy for people with cancer.



We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognise and attack diverse cancer cells in each patient. The company's first product, AMTAGVI (lifileucel), an autologous T-cell therapy using TIL, was recently approved by the Therapeutic Goods Administration (TGA) and is indicated for the treatment of advanced melanoma. Iovance is preparing to launch this novel treatment in the Australian market.

Essential Functions and Responsibilities

- Own and lead the Australian commercialisation strategy, launch plan and ongoing business performance for AMTAGVI and Proleukin.
- Hold profit-and-loss accountability for the Australian business, including revenue, operating expenses, forecasts, budgets, investments, resource allocation and profitability.
- Establish annual and long-range commercial plans, performance measures and resource priorities aligned with global business objectives.
- Lead the full sales cycle across authorised treatment centres and referral networks, from opportunity identification, account planning and customer education through patient identification, referral, treatment scheduling, completed infusion, revenue generation and ongoing account growth.
- Achieve patient infusion, demand and revenue targets for AMTAGVI and Proleukin while maintaining compliance with applicable laws, regulations and company policies.




- Build and manage the Australian commercial forecast using treatment‐centre readiness, referral activity, patient identification, scheduling, manufacturing, infusion and revenue data.
- Develop and maintain executive, clinical and operational relationships with treatment centres, referral sites, health-service leaders, clinicians, Commonwealth and state health authorities, public and private funders, reimbursement stakeholders, hospital decision-makers and other partners required to establish and expand TIL therapy in Australia.
- Lead the TIL treatment‐centre authorisation process using risk‐based tools for authorisation, training, monitoring and disqualification, and provide ongoing operational and quality oversight of authorised treatment centres.
- Lead operational meetings with medical leadership from medical oncology, surgery and cell therapy to establish a standard‐of‐care pathway for TIL therapy.
- Lead cross‐functional treatment‐centre meetings with nursing, laboratory, pharmacy, quality and operational champions to develop product and patient workflows and remove barriers to treatment.
- Develop and execute training for authorised users and ensure access to chain‐of‐identity and chain‐of‐custody systems is provided to trained individuals.
- Lead cross‐functional execution across Market Access, Treatment Centre Operations, Medical Affairs, Business Analytics, Finance, Human Resources, Legal, Supply Chain, Patient Services and global commercial teams.
- Serve as the senior business representative for Australia in global planning, forecasting, investment and performance reviews.
- Design the future Australian commercial organisation and lead the selection, development and performance

📌 Commercial Lead, Australia (Sydney)
🏢 Wwshemi
📍 Sydney